Skip to content
Screener

Cogent Biosciences, Inc. COGT Q2 2025 earnings

Reported August 5, 2025 · Before market open

EPS-$0.53Beat by $0.02
EPS estimate-$0.55

Next report

Aug 10, 2026 (In 3 days)
Revenue estimate$1.0K
EPS estimate-$0.55

Financials

Q2 2025

Income statement

See full
Operating income-$75.6M-17.4%
Net income-$73.5M-24.7%
EPS (diluted)-$0.53-23.3%

Balance sheet

See full
Cash & equivalents$127.6M+44.6%
Total debt$60.7M+234%
Total equity$155.0M-58.5%
Total assets$274.8M-36.1%

Cash flow

See full
Operating cash flow-$54.5M-27.7%
CapEx$131.0K-11.5%
Free cash flow-$54.7M-27.6%

Valuation & ratios

Valuation

as of 06/30/25
See full
Market cap$824.32M-10.6%
Enterprise value$757.38M-11.1%

Returns & leverage

See full
Return on equity-107.6%+262pp
Debt / equity0.4×+0.3×
Current ratio4.2×-5.1×

FAQ

When did Cogent Biosciences, Inc. report Q2 2025 earnings?
Cogent Biosciences, Inc. (COGT) reported Q2 2025 earnings on August 5, 2025 before market open.
What were Cogent Biosciences, Inc.'s Q2 2025 revenue and EPS?
Cogent Biosciences, Inc. reported eps of $-0.53 for Q2 2025.
Did Cogent Biosciences, Inc. beat estimates in Q2 2025?
EPS beat the consensus estimate of $-0.55 by $0.02.
How did Cogent Biosciences, Inc.'s Q2 2025 results compare year-over-year?
Compared to the same quarter a year prior, eps grew 10.2% from $-0.59.
Where can I find Cogent Biosciences, Inc.'s Q2 2025 SEC filings?
You can read the 8-K earnings release (0000950170-25-102433) and the 10-Q periodic report (0000950170-25-102440) directly on SEC EDGAR. The filing index links above go to sec.gov.